Global Oncology/Cancer Industry Analysis and Forecast 2016-2020

  • ID: 3787080
  • Report
  • Region: Global
  • 429 Pages
  • Maxvey
1 of 5
This report about Cancer Market Forecast Chemotherapy Drug Industry 2016-2020, Cancer Drugs Market by Therapeutic Method, Cancer Diagnostics Market by Application Clinical Trials and Health Care Delivery System, Cancer Control Worldwide Outlook, Cancer Control Plans and Cancer Control Research, Worldwide Cancer New Cases, mortality and Risk factors, Market Dynamics, Challenges, Opportunities and Strategies.

This Report on Cancer Diseases is the first worldwide report on the state of Cancers and ways to map the epidemic reduce its major risk factors and strengthen health care for people who already suffer from cancers.

In this report mention the foundation of new and better approaches to cancer prevention, detection, diagnosis, and treatment, which are driving down overall cancer death rates and increasing the number of people who are living longer, higher-quality lives after a cancer diagnosis.

The Report main focuses on the current global status of Cancers and will be followed by another report to assess progress in 2016. One of the main objectives of this report is to provide a baseline for countries on the current status of cancers and their risk factors, as well as the current state of progress countries are making to address these diseases in terms of policies and plans, infrastructure, surveillance and population-wide and individual interventions. It also disseminates a shared vision and road map for Cancer prevention and control. Target audiences include policy- makers, health officials, nongovernmental organizations, academia, relevant non-health sectors, development agencies and civil society.

Purpose of the Report:

The aim of this is report to provide detailed information regarding incidence, mortality, survival and other measures of cancer burden for the most common types of cancer. Data are presented by sex, age and province or territory. Trends over time are also examined. The report is designed to help health professionals, policy-makers and researchers identify and make decisions about new areas for investigation. The media, educators and members of the public with an interest in cancer will also find this publication valuable.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
1 Executive Summary
1.1 Industry Overview
1.2 Worldwide Cancer Diagnostics Market 2016-2020
1.3 Cancer Diagnostics Market Segmentation
1.4 Global Market Analysis And Pipeline Analysis
1.5 Competitive Landscape
1.6 About This report
1.7 Scope of The Report
1.8 Methodology
1.9 Objectives of the study

2 Cancer Basic Facts and Cancer Diagnostics Global Market Analysis 2016-2020
2.1 What is Cancer?
2.2 Worldwide New Cancer Cases and Deaths Occurred
Figure 1 Worldwide Leading Causes of death in 2015-2016
Figure 2 Worldwide Common Cancers in 2016
Figure 3 New Cancer Cases and deaths- Estimates 2015 - 2016 FEB.
2.3 Geographic, Statistic and Demographic Cancer Occurrence
2.4 Stages of Cancer
2.5 The cost of cancer
2.6 Interventions for Cancer Prevention and Control
2.7 Cancer Genetic Risk Factors
Figure 4 Developed Countries cancer causes by Economic Development
Figure 5 Developing Countries cancer causes by Economic Development
2.8 Survival percentage of Cancer
2.9 Current and future challenges posed by Cancer
2.10 Cancer Diagnostics Classification Methods and Models
Figure 6 Automatic Cancer Detection Model
Figure 7 CLAHE images Original and Enhanced
Figure 8 Original and K-means segmentation approach
Table 1 Quantitative evaluation of segmentation methods
Figure 9 Comparisons of Segmentation Methods
2.11 Cancer Diagnostics Market Size and Forecast
2.12 Cancer Diagnostics Market Development Overview
Common Cancers Description, Diagnosis, Statistic, Risk Factors and Next

3 Generation Treatment 2016-2020
3.1 Common Cancer
Table 2 New cases and deaths for each common cancer type 2016
3.2 Types of Cancers
3.3 Bladder Cancer: Overview, Diagnosis, Statistics
3.3.1 Symptoms and Signs
3.3.2 Stages and Grades
3.3.3 Medical care Foll-up
Figure 10 Human body parts affected by Bladder Cancer
3.3.4 Risk Factors of Bladder Cancer
3.3.5 Bladder Cancer Treatment Options
3.4 Breast Cancer: Overview, Diagnosis, Statistics,
3.4.1 Symptoms and Signs
3.4.2 Stages and Grades
Figure 11 Stage 0 Ductal carcinoma in situ (DCIS)
Figure 12 Stage 0 Lobular carcinoma in situ (LCIS)
Figure 13 Stage 1A and Stage 1B Breast Cancer
Figure 14 Stage IIA Breast Cancer
Figure 15 Stage IIB Breast Cancer
Figure 16 Stage IIIA Breast Cancer
Figure 17 Stage IIIB Breast Cancer
Figure 18 Stage IIIC Breast Cancer
Figure 19 Stage IV Breast Cancer
3.4.4 Risk Factors of Bladder Cancer
3.4.3 Medical care Foll-up
3.4.4 Risk Factors of Breast Cancer
3.4.5 Breast Cancer Treatment Options
3.4 Colorectal Cancer: Overview, Diagnosis, Statistics
3.4.1 Symptoms and Signs
3.4.2 Stages and Grades
3.4.3 Medical care Foll-up
Figure 20 Human body parts affected by Colorectal Cancer
3.4.4 Risk Factors of Colorectal Cancer
3.4.5 Colorectal Cancer Treatment Options
3.5 Kidney Cancer: Overview, Diagnosis, Statistics
3.5.1 Symptoms and Signs
3.5.2 Stages and Grades
Figure 21 kidney Cancer by the following stages
3.5.3 Medical care Foll-up
3.5.4 Risk Factors of Colorectal Cancer
3.5.5 Colorectal Cancer Treatment Options
3.6 Lung Cancer: Overview, Diagnosis, Statistics
3.6.1 Symptoms and Signs
3.6.2 Stages and Grades
3.6.3 Medical care Foll-up
Figure 22 Human body parts affected by Lung Cancer
3.7 Lymphoma - Non-Hodgkin: Overview, Diagnosis, Statistics
3.7.1 Symptoms and Signs
3.7.2 Stages and Grades
3.7.3 Medical care Foll-up
3.7.4 Risk Factors of Lymphoma
3.7.5 Lymphoma Treatment Options
Figure 23 Human body parts affected by Lymphoma
3.8 Melanoma: Overview, Diagnosis, Statistics
3.8.1 Symptoms and Signs
3.8.2 Stages and Grades
3.8.3 Medical care Foll-up
3.8.4 Risk Factors of Melanoma
3.8.5 Melanoma Treatment Options
Figure 24 Human body parts affected by Melanoma
3.9 Oral and Oropharyngeal Cancer: Overview, Diagnosis, Statistics
3.9.1 Symptoms and Signs
3.9.2 Stages and Grades
3.9.3 Coping with Side Effects
3.9.4 Risk Factors of Oropharyngeal Cancer
3.9.5 Oropharyngeal Cancer Treatment Options
Figure 25 Human body parts affected by and Oropharyngeal Cancer
3.10 Pancreatic Cancer: Overview, Diagnosis, Statistics
3.10.1 Symptoms and Signs
3.10.2 Stages and Grades
3.10.3 Medical care Foll-up
3.10.4 Risk Factors of Pancreatic Cancer
3.10.5 Pancreatic Cancer Treatment Options
Figure 26 Human body parts affected by Pancreatic Cancer
3.11 Prostate Cancer: Overview, Diagnosis, Statistics
3.11.1 Symptoms and Signs
3.11.2 Stages and Grades
3.11.3 Medical care Foll-up
3.11.4 Risk Factors of Prostate Cancer
3.11.5 Prostate Cancer Treatment Options
Figure 27 Human body parts affected by Prostate Cancer
3.12 Thyroid Cancer: Overview, Diagnosis, Statistics
3.12.1 Symptoms and Signs
3.12.2 Stages and Grades
3.12.3 Medical care Foll-up
3.12.4 Risk Factors of Thyroid Cancer
3.12.5 Thyroid Cancer Treatment Options
Figure 28 Human body parts affected by Thyroid Cancer
3.13 Uterine Cancer
3.13.1 Symptoms and Signs
3.13.2 Stages and Grades
3.13.3 Coping with Side Effects
3.13.4 Risk Factors of Uterine Cancer
3.13.5 Uterine Cancer Treatment Options
Figure 29 Human body parts affected by Uterine Cancer

4 Global Cancer Diagnoses Market, by Techniques 2016-2020
4.1 Barium Enema
4.2 Bone Marrow Aspiration and Biopsy
4.3 Breast MRI for The Early Detection Brest Cancer
4.4 Colonoscopy
4.5 Digital Rectal Exam (DRE)
4.6 Donating Bone Marrow
4.7 EKG and Echocardiogram
4.8 Fecal Occult Blood Tests
4.9 Mammography
4.10 Pap Test
4.11 Ultrasound
4.12 Biopsy
4.13 Bone Scan
4.14 Brest MRI
4.15 Computed Tomography (CT) Scan
4.16 Donating Blood and Platelets
4.17 Donating Umbilical Cord Blood
4.18 Types Of Endoscopy
4.18 Magnetic Resonance Imaging (MRI)
4.19 MUGA Scan
4.20 Positron Emission Tomography and Computed Tomography (PET-CT) Scans
4.21 Tumor Marker Tests
4.22 Upper Endoscopy

5 Worldwide Cancer Diagnostics Market, By Application
5.1 Worldwide Cancer Diagnostics Market
5.1.1 Worldwide Cancer Diagnostics Market Revenue, by Geography 2016-2020 (USD) Million
5.1.2 Comparative Analysis: Worldwide Cancer Diagnostics Market Forecast by Application, 2016-2020
5.2 Breast Cancer Therapeutics Market by Geography
5.2.1 North America
5.2.2 Latin America
5.2.3 Europe
5.2.4 Asia
5.2.5 Middle East
5.2.6 Africa
Table 3 Global New Female Breast Cancer Cases and Deaths 2016
Figure 30 New Breast Cancer Cases 2016
5.3 Breast Cancer Therapeutics Market by Drug Class
5.3.1 HER2 Inhibitors
5.3.2 Mitotic Inhibitors
5.3.3 Anti-metabolites
5.3.3 Aromatase Inhibitors
5.3.4 Hormone Receptors
Figure 31 Breast Cancer Therapeutics Market by Drug Class
5.4 Lung Cancer Therapeutics Market by Geography
5.4.1 North America
5.4.2 Latin America
5.4.3 Europe
5.4.4 Asia
5.4.5 Middle East
5.4.6 Africa
5.5 Lung Cancer Therapeutics Market by Drug Class
5.5.1 Hycamtin
5.5.2 Taxotere
5.5.3 Gemzar
5.5.4 Alimta
5.5.5 Iressa
5.5.6 Avastin
5.5.7 Tarceva
5.5.8 Pipeline Drugs
Figure 32 Lung Cancer Therapeutics Market by Drug Class
5.6 Colorectal Cancer Therapeutics Market by Geography
5.6.1 North America
5.6.2 Latin America
5.6.4 Asia
5.6.5 Middle East
5.6.6 Africa
Figure 33 Colorectal Cancer Drugs Market by Global Market Share 2016
5.7 Melanoma Therapeutics Market by Geography
5.7.1 North America
5.7.2 Latin America
5.7.3 Europe
5.7.4 Asia
5.7.5 Middle East
5.7.6 Africa
Figure 34 Melanoma Therapeutics Market 2016-2020

6 Global Cancer New Cases, mortality and Risk factors
6.1 Leukemia: Number of new cases, deaths and Risk Factors
6.1.1 Leukemia: Number of new cases by Age Group
Figure 35 Leukemia Number of new cases by Age Group
Figure 36 No of New Cases by Race/Ethnicity & Sex: Leukemia
Figure 37 Number of Death by Age Group: Leukemia
Figure 38 Number of Death by Male & Female: Leukemia
Table 4 Number of New Cases and Deaths per 100,000 Leukemia
6.2 Brest Cancer: Number of new cases, deaths and Risk Factors
Figure 39 Brest Cancer Number of new cases by Age Group
Figure 40 No of New Cases by Race/Ethnicity & Sex: Brest Cancer
Figure 41 Number of Death by Age Group: Brest Cancer
Figure 42 Number of Death by Male & Female: Brest Cancer
Table 5 Number of New Cases and Deaths per 100,000 Brest Cancer
6.3 Colorectal Cancer: Number of new cases, deaths and Risk Factors
Figure 43 Colorectal Cancer Number of new cases by Age Group
Figure 44 No of New Cases by Race/Ethnicity & Sex: Colorectal Cancer
Figure 45 Number of Death by Age Group: Colorectal Cancer
Figure 46 Number of Death by Male & Female: Colorectal Cancer
Table 6 Number of New Cases and Deaths per 100,000 Colorectal Cancer
6.4 Kidney Cancer: Number of new cases, deaths and Risk Factors
Figure 47 Kidney Cancer Number of new cases by Age Group
Figure 48 No of New Cases by Race/Ethnicity & Sex: Kidney Cancer
Figure 49 Number of Death by Age Group: Kidney Cancer
Figure 50 Number of Death by Male & Female: Kidney Cancer
Table 7 Number of New Cases and Deaths per 100,000 Kidney Cancer
6.5 Liver Cancer: Number of new cases, deaths and Risk Factors
Figure 51 Liver Cancer Number of new cases by Age Group
Figure 52 No of New Cases by Race/Ethnicity & Sex: Liver Cancer
Figure 53 Number of Death by Age Group: Liver Cancer
Figure 54 Number of Death by Male & Female: Liver Cancer
Table 8 Number of New Cases and Deaths per 100,000 Liver Cancer
6.6 Lung Cancer: Number of new cases, deaths and Risk Factors
Figure 51 Lung Cancer Number of new cases by Age Group
Figure 52 No of New Cases by Race/Ethnicity & Sex: Lung Cancer
Figure 53 Number of Death by Age Group: Lung Cancer
Figure 54 Number of Death by Male & Female: Lung Cancer
Table 9 Number of New Cases and Deaths per 100,000 Lung Cancer
6.7 Ovarian Cancer: Number of new cases, deaths and Risk Factors
Figure 55 Ovarian Cancer: Number of new cases by Age Group
Figure 56 No of New Cases by Race/Ethnicity & Sex: Ovarian Cancer
Figure 57 Number of Death by Age Group: Ovarian Cancer
Figure 58 Number of Death by Male & Female: Ovarian Cancer
Table 10 Number of New Cases and Deaths per 100,000 Ovarian Cancer
Figure 59 Pancreatic Cancer: Number of new cases by Age Group
Figure 60 No of New Cases by Race/Ethnicity & Sex: Pancreatic Cancer
Figure 61 Number of Death by Age Group: Pancreatic Cancer
Figure 62 Number of Death by Male & Female: Pancreatic Cancer
Table 11 Number of New Cases and Deaths per 100,000 Pancreatic Cancer
6.9 Prostate Cancer: Number of new cases, deaths and Risk Factors
Figure 63 Prostate Cancer: Number of new cases by Age Group
Figure 64 No of New Cases by Race/Ethnicity & Sex: Prostate Cancer
Figure 65 Number of Death by Age Group: Prostate Cancer
Figure 66 Number of Death by Male & Female: Prostate Cancer
Table 12 Number of New Cases and Deaths per 100,000 Prostate Cancer
6.10 Thyroid Cancer: Number of new cases, deaths and Risk Factors
Figure 67 Thyroid Cancer: Number of new cases by Age Group
Figure 68 No of New Cases by Race/Ethnicity & Sex: Thyroid Cancer
Figure 69 Number of Death by Age Group: Thyroid Cancer
Figure 70 Number of Death by Male & Female: Thyroid Cancer
Table 13 Number of New Cases and Deaths per 100,000 Thyroid Cancer
6.11 Endometrial cancer: Number of new cases, deaths and Risk Factors
Figure 71 Endometrial cancer Number of new cases by Age Group
Figure 72 No of New Cases by Race/Ethnicity & Sex: Endometrial cancer
Figure 73 Number of Death by Age Group: Endometrial cancer
Figure 74 Number of Death by Male & Female: Endometrial cancer
Table 14 Number of New Cases and Deaths per 100,000 Endometrial cancer

7 Global Cancer: Market Dynamics, Challenges, Opportunities and Strategies 2016-2020
7.1 Introduction
7.2 Market Dynamics
7.2.1 Rising incidence of Second cancers
Figure 75 Global Cancer Predicted Cases 2016-2020 (Millions)
7.3 Importance of Targeted and Biologic Cancer Therapies
7.4 Key impact of Biosimilars Drugs
7.5 Global Health Organizations Cancer Control Principals
7.1.5 Improving Personalized Cancer Treatment Plans for Patients
7.6 Top Global Cancer Challenges of the 21st Century
7.6.1 High Price of drug development
7.7 Side Effects of Anti-cancer Drugs
7.7.1 Side Effects of Surgery
7.7.2 Side Effects of Radiation Therapy
7.7.3 Chemotherapy Side Effects
7.7.4 Hormone Therapy Side Effects
7.7.5 Side Effects of Biological Therapy / Immunotherapy
7.7.6 Side Effects of Bone Marrow Transplantation (BMT)
7.8 Development of anti-cancer drugs research
7.9 Personalized medicine approach

8 Worldwide Cancer Drugs Market by Therapeutic Method
Figure 76 Therapeutic Cancer Drug Spend per Capita 2012-2016
8.1 Chemotherapy Overview
Figure 77 Patients chemotherapy at the end of life in 2010, 2012, and 2015
Figure 78 Patients oral Chemotherapeutic in 2010, 2012 and 2015
8.1.1 Market Trend Chemotherapy for advanced cancer patients
8.1.2 Statistical Analysis
8.1.3 Goal of Chemotherapy
Figure 79 Market Forecast Chemotherapy Drug Industry 2016-2020
8.2 Overview of Targeted Therapies for Cancer
8.2.1 Targeted therapies types used to treat cancer
8.2.2 Various types of targeted drugs
8.2.3 Side effects of targeted cancer therapy drugs
8.2.4 Targeted Therapy New Generation of Cancer Treatments
8.2.5 Targeted Therapy Future Directions
8.2.6 Market Forecast Targeted Therapy Drug Industry 2016-2020
8.3 Immunotherapy (biologics therapy)
8.3.1 Risk Factors Immunotherapy
8.3.2 Progress and challenges in the clinical
8.3.3 Immunotherapy Future developments for cancer patients
8.3.4 Global Spending Statistic on Immunotherapy 2016-2020
Figure 80 Global Spending Statistic on Immunotherapy 2016-2020
8.3.5 Market Forecast Immunotherapy Drug Industry 2016-2020
8.4 Hormonal Therapy
8.4.1 Different types of hormone therapy
8.4.2 Facts, Risk and Benefits Hormonal Therapy
8.4.3 Side of Hormonal Therapy
8.5 Others Therapy

9 Global Cancer Control Plans and Cancer Control Research
9.1 Cancer Control: A Worldwide Outlook
9.1.1 The National Cancer Plan 2016-2020
9.1.2 Goals of National Cancer Control Programmes
Figure 81 Components of National Cancer Control Programme
Figure 82 Comprehensive Cancer Control Planning
9.1.3 Components of National Cancer Control Programmes
9.1 4 National Cancer Control Achievements
9.1.5 Barriers to effective National Cancer Control
9.1.6 Impact of cancer control
9.2 Cancer in Developing Countries
9.2.1 Challenges Facing Developing Countries
9.2.2 Cancer Control in Developing Countries
Figure 83 Incidence of cancers- Developed Vs Developing Countries
9.3 Cancer control in Europe today: Challenges and Policy
Figure 84 Estimated Incidence of Cancer in Europe 2015-2016
9.4 Challenge of Cancer in Africa
9.4.1 Comparative Rates of Cancers in Africa
Figure 85 Most Commonly Diagnosed Cancers in Africa (2015-2016)
9.5 Cancer Control in the Asia Pacific
9.5.1 Asia: dynamics of cancer burden
9.5.2 Preventable Risk factors
Figure 86 Comparison of age-standardized cancer incidence Asia 2015-2016
9.5 Cancer in Canada
Figure 87 Proportion of Deaths due to cancer causes in Canada 2015-2016
9.6 Cancer in the Middle East
9.6.1 Cancer Patients Faced Challenges in Treatment
Figure 88 Incidence of cancers in the Middle East
9.6.2 Prostate Cancer in the Middle East
9.6.3 Challenges and Opportunities in Establishing Care Services
9.7 Cancer Control Research
9.7.1 Research Aims
9.7.2 Major Areas of Research
9.7.3 Phases of Research
Figure 89 Classification of cancer control research by phase
9.7.4 Promoting Evidence based Cancer control
9.7.5 Priorities for Global Cancer Research

10 Clinical Trials and Health Care Delivery System Improvement
10.1 Advanced Clinical Trials
10.2 Phases of Clinical Trials
10.2.1 Care in Phases of Clinical Trials
10.3 Types of Clinical Trials
10.3.1 Benefits of Clinical Trials
10.4 Eligible for a Clinical Trial
10.5 Advantages and Disadvantages Clinical Trials
10.6 Clinical trials for prostate cancer
10.7 Questions to ask your doctor or nurse
10.8 Protections and Rights in a clinical Trial
10.9 Cancer Care Support System
10.10 Clinical Trial Finish Process

11 Worldwide Cancer Death Rate Ranking Forecasts 2015-2016
Table 15 Lung Cancer Worldwide Ranking Forecast 2015-2016
Table 16 Breast Cancer Worldwide Ranking Forecast 2015-2016
Table 17 Bladder Cancer Worldwide Ranking Forecast 2015-2016
Table 18 Liver Cancer Worldwide Ranking Forecast 2015-2016
Table 19 Prostate Cancer Worldwide Ranking Forecast 2015-2016
Table 20 Stomach Cancer Worldwide Ranking Forecast 2015-2016
Table 21 Cervical Cancer Worldwide Ranking Forecast 2015-2016
Table 22 Leukemia Worldwide Ranking Forecast 2015-2016
Table 23 Colon Rectum Cancers Worldwide Ranking Forecast 2015-2016

12 12 Recommendations and Conclusion
12.1 Research Agenda
12.2 Scope
12.3 Market Forecast
12.4 Key Findings of the Report
12.5 Summary
12.6 Conclusion
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Cancer are the leading global causes of death, causing more deaths than all other causes combined, and they strike hardest at the world‘s low- and middle-income populations. these diseases have reached epidemic proportions, yet they could be significantly reduced, with millions of lives saved and untold suffering avoided, through reduction of their risk factors, early detection and timely treatments.

Cancer is a generic term for a large group of diseases that can affect any part of the body, characterized by uncontrolled growth and spread (or metastasis) of abnormal cells. As such, there is an urgent need for diagnostic tests to detect cancer earlier, allowing physicians to make more informed therapeutic decisions. Recently, the growth in this field has been extremely rapid with a large number of tumor markers being identified. Tumor markers are a group of proteins, hormones, enzymes, receptors and other cellular products that are over-expressed (i.e., produced in higher than normal amounts) by malignant (cancerous) cells. Tumor markers are sometimes normal cellular constituents that are present at normal or very low levels in the blood of healthy individuals.

All cancers involve the malfunction of genes that control cell growth, division and death. As such, scientists are working hard to develop tests based on molecular and genetic RNA/DNA that can detect individuals at high risk for specific cancers. These include serological assays, cellular assays and molecular and genetic assays. Some of the most widely-tested and clinically-utilized diagnostic tumor markers include prostate-specific antigen (PSA) for prostate cancer, alpha-fetoprotein (AFP) for liver cancer, carcinoembryonic antigen (CEA) for colon cancer, carbohydrate antigen (CA)-125 for ovarian cancer, CA 19-9 for gastrointestinal cancer, the ß sub-unit of human chorionic gonadotropin (ß-hCG) in germ cell tumors, and CA 15-3 and CA 27.29 for breast cancer. With the rapid development of new systems and methodologies for diagnostic testing, early diagnosis and successful treatment of cancer is now a reality.

Global cancer prevalence rates are on the rise owing to an aging population and changing lifestyle. Prevalence data is influenced by the increasing diagnosis and survival rates across the global market.

Globally, lung cancer is one of the most common types of cancer, with an estimated 1.2 million new cases being diagnosed every year. Among all lung cancer cases, approximately 42% survive after one year, yet the relative five- year survival rate for all lung cancers combined is approximately 15% only.

The last decade has seen a significant fall in mortality rates from breast cancer. Owing to the lack of medical treatments for late-stage breast cancer, the long-term survival of patients still depends on early diagnosis, which has been improved through the contentious use of large-scale screening and public awareness programs.

Prostate cancer is one of the most commonly diagnosed cancers and is the second leading cancer related cause of death in men, surpassed only by lung cancer. The highest incidence of this disease is seen in the US, and studies have placed black men at a higher risk of prostate cancer than men from other ethnic origins.

Globally, colorectal cancer (CRC) is the second most commonly diagnosed form of cancer. In 2015, approximately 2.9 million individuals were affected by CRC in the seven major markets (7MM). The incidence of CRC increases with age, generally occurring in the sixth or seventh decade of life.

Mortality rates, particularly among men, appear set to rise steadily over the next five years, despite the positive impact of screening on the early identification of the disease.

Pancreatic cancer is most common in men and women between the ages of 60 and 75, making age the predominant risk factor for incidence of the disease. In the seven major markets, prevalence is projected to grow modestly to 80 million in 2020. The low prevalence of the disease can be attributed to late diagnosis, poor prognosis, and low survival.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll